Home > Quotes > BSX

Boston Scientific Corporation Stock Quote & Summary Data

BSX 
$9.4
*  
0.14
  negative  
1.47%
Get BSX Alerts
*Delayed - data as of Jun. 19, 2013 
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    BSX After Hours
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 | Sponsored

1 Year Target: 8
Today's High/Low:  / 
Share Volume:
90 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today’s trading to the average daily volume. 18,762,112
Previous Close: $ 9.54
52 Week High /Low: $ 9.75 / $ 4.79
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. $ 12,681,468,410
P/E Ratio: NE
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year. 14.24
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ -3.13
Annualized dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield 0 %
Beta 0.99

 Intraday Chart

5d | 1m | 6m | 12m | More Charting

ETFs with BSX as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
4.45% iShares Dow Jones U.S. Medical Devices Index Fund (IHI) +6.66  (9.02%)
2.44% SPDR S&P Health Care Equipment (XHE) +7.40  (12.97%)
2.24% Guggenheim S&P 500 Equal Weight Healthcare ETF (RYH) +11.62  (13.72%)

We make it easy to follow the leaders. PowerShares QQQ. 100 companies at the top of innovation in one fund.


*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.

**Green highlights the top performing ETF by % change in the past 100 days.

 Company Description (as filed with the SEC)

Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. When used in this report, the terms “we,” “us,” “our” and “the Company” mean Boston Scientific Corporation and its divisions and subsidiaries. Our history began in the late 1960s when our co-founder, John Abele, acquired an equity interest in Medi-tech, Inc., a research and development company focused on developing alternatives to surgery. In 1969, Medi-tech introduced a family of steerable catheters used in some of the first less-invasive procedures performed. In 1979, John Abele joined with Pete Nicholas to form Boston Scientific Corporation, which indirectly acquired Medi-tech.  ... More ...  



News Headlines for BSX

BSX Commences U.S. INTREPID Trial - Analyst Blog
6/18/2013 3:20:01 PM - Zacks.com
Boston Scientific Vercise™ DBS System demonstrates Improvement In Motor Function For Patients With Parkinson's Disease
6/18/2013 12:00:00 AM - PR Newswire
Boston Scientific Announces First Implantation Of Vercise DBS System
6/17/2013 5:27:00 PM - RTT News
Boston Scientific Begins Patient Enrollment In U.S. Clinical Trial For Use Of Vercise™ DBS System In Treatment Of Parkinson's Disease
6/17/2013 5:03:00 PM - PR Newswire
Gloomy Prospects For Medical Device Companies
6/16/2013 6:46:00 AM - Seeking Alpha
 

Consensus Recommendation